EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC 4.0

Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry

Marc Thill, Mark-Oliver Zahn, Anja Welt iD, Arnd Nusch, Matthias Zaiss, Kathrin Engelken, Gabriele Kaltenecker, Kai Ringwald, Katja Gratzke, Stephanie Dille, Lisa Kruggel, Martina Jänicke und 7 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35296 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Marc Thill und 18 weiteren Autor:innen. Beteiligte Einrichtung: Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Gynäkologische Onkologie, Brustzentrum, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Purines, Pyridines, Aminopyridines. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer GmbH, Roche Pharma AG, Eisai GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin‐dependent kinase 4/6 inhibitors (CDKIs) in combination with endocrine therapy (ET) are the standard‐of‐care in the first‐line treatment of HR‐positive, HER2‐negative metastatic breast cancer. In the absence of direct head‐to‐head trials comparing the efficacy and safety of the different CDKIs, the individual choice of treatment in everyday practice is complex. Inverse probability of treatment weighting was used to emulate a head‐to‐head comparison of palbociclib +ET (PALBO) and ribociclib +ET (RIBO) in patients recruited into the prospective, observational, multicenter registry platform OPAL (NCT03417115). Progression‐free survival (PFS), overall survival (OS) and quality of life surveys were analyzed, also for subgroups stratified by treatment‐free interval (TFI). A total of 623 patients with HR‐positive, HER2‐negative metastatic breast cancer received PALBO ( n = 388) or RIBO ( n = 235) in their first line of treatment. No difference between PALBO and RIBO was found for PFS (median 26.7 months [23.6, 30.7] vs. 27.0 months [21.1, 30.4], HR 1.01 [0.80, 1.27]) and OS (median 42.4 months [38.8, 50.3] vs. 49.3 months [36.9, NA], HR 0.96 [0.71, 1.28]). There was a trend for longer PFS and OS in patients with TFI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPurinesPyridinesAminopyridinesPiperazinesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesAgedRegistriesAdultProspective StudiesReceptors, ProgesteroneReceptors, EstrogenAged, 80 and overQuality of LifeProgression-Free Survival

Stichwörter der Autor:innen

breast neoplasmspalbociclibregistriesribociclib

Substanzen

PurinesPyridinesAminopyridinesPiperazinesErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenribociclibpalbociclibERBB2 protein, human

Autor:innen und Institutionen

  • Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Gynäkologische Onkologie, Brustzentrum, Frankfurt am Main, Germany.
  • MVZ Onkologische Kooperation Harz, Goslar, Germany.
  • Innere Klinik, Tumorforschung, Universitätsklinikum Essen, Essen, Germany.
  • Praxis für Hämatologie und internistische Onkologie, Ratingen, Germany.
  • Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany.
  • Klinik Dr. Hancken, Mammazentrum, Stade, Germany.

ORCID-Profile: Anja Welt, Thomas Decker

Förderung

  • Pfizer GmbH
  • Roche Pharma AG
  • Eisai GmbH
  • Lilly Deutschland GmbH
  • Mundipharma GmbH
  • Mylan Germany GmbH
  • Onkovis GmbH
  • Daiichi Sankyo Deutschland GmbH

Zitieren

APA

Thill, M., Zahn, M. O., Welt, A., Nusch, A., Zaiss, M., Engelken, K., Kaltenecker, G., Ringwald, K., Gratzke, K., Dille, S., Kruggel, L., Jänicke, M., Schulz, H., Hagen, V., Fricker, R., Stickeler, E., Harbeck, N., Wöckel, A., & Decker, T. (2025). Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry. International Journal of Cancer. https://doi.org/10.1002/ijc.35296

Vancouver

Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, et al. Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry. International Journal of Cancer. 2025. doi:10.1002/ijc.35296

BibTeX
@article{Thill2025,
  author = {Thill, Marc and Zahn, Mark-Oliver and Welt, Anja and Nusch, Arnd and Zaiss, Matthias and Engelken, Kathrin and Kaltenecker, Gabriele and Ringwald, Kai and Gratzke, Katja and Dille, Stephanie and Kruggel, Lisa and Jänicke, Martina and Schulz, Holger and Hagen, Volker and Fricker, Roland and Stickeler, Elmar and Harbeck, Nadia and Wöckel, Achim and Decker, Thomas},
  title = {Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35296}
}
Kostenlos starten →